PTGX vs SYRE: stock comparison and AI forecast
Protagonist Therapeutics, Inc (PTGX) and Spyre Therapeutics, Inc. (SYRE) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
PTGX Protagonist Therapeutics, Inc
- Price
- $132.04 +33.6% · 6M
- Market Cap
- $8.54B
- P/E Ratio
- 33.6x
- Size
- mid-cap
- AI Forecast
SYRE Spyre Therapeutics, Inc.
- Price
- $103.86 +42.1% · 6M
- Market Cap
- $9.16B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- PTGX and SYRE have similar market capitalizations ($8.54B and $9.16B).
- Over the last six months SYRE returned +42.1% and PTGX +33.6%.
- PTGX carries 0.06 times debt per unit of equity, against 0.05 times for SYRE.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | PTGX | SYRE |
|---|---|---|
| Market Cap | $8.54B | $9.16B |
| P/E Ratio | 33.60x | – |
| P/B Ratio | 7.88x | 8.71x |
| EPS | $3.93 | $-2.19 |
| Book Value/Share | $16.77 | $11.93 |
| Revenue/Share | $3.39 | – |
| FCF/Share | $1.69 | – |
Profitability & Margins
| Metric | PTGX | SYRE |
|---|---|---|
| ROE | 31.6% | -25.1% |
| ROA | 29.9% | -24.0% |
| ROIC | 29.6% | -23.6% |
| Operating Margin | 147.1% | – |
| Net Margin | 155.8% | – |
| EBT Margin | 158.4% | – |
| Tax Rate | 2.3% | 0.0% |
Financial Health
| Metric | PTGX | SYRE |
|---|---|---|
| Current Ratio | 19.85x | 27.40x |
| D/E Ratio | 0.06x | 0.05x |
| Financial Leverage | 1.06x | 1.05x |
| Working Capital | $1.05B | $1.06B |
Cash Flow
| Metric | PTGX | SYRE |
|---|---|---|
| Operating Cash Flow | $110M | -$249M |
| Free Cash Flow | $109M | – |
| Capital Spending | -$760K | – |
| OCF Growth YoY | 67.9% | – |
| FCF Growth YoY | 71.3% | – |
| FCF/Sales | 49.7% | – |
| CapEx/Sales | 0.3% | – |
Operational Efficiency
| Metric | PTGX | SYRE |
|---|---|---|
| Asset Turnover | 0.19x | – |
| Fixed Assets Turnover | 66.1x | – |
Income Statement
| Metric | PTGX | SYRE |
|---|---|---|
| Total Revenue | $220M | – |
| Operating Income | $323M | -$250M |
| Net Income | $342M | -$264M |
| R&D Expense | $176M | $260M |
Dividend & Shareholder Information
| Metric | PTGX | SYRE |
|---|---|---|
| Shares Outstanding | 65M | 88M |
| Net Income Growth | 645.5% | – |
| EPS Growth | 182.7% | – |
PTGX vs SYRE: stock comparison and AI forecast
Which is bigger, PTGX or SYRE?
PTGX and SYRE have similar market capitalizations ($8.54B and $9.16B).
Which stock performed better over the last six months, PTGX or SYRE?
Over the last six months SYRE returned +42.1% and PTGX +33.6%.
Which one does Intratio's AI model rank higher, PTGX or SYRE?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.